预约演示
更新于：2025-10-28
Brinzolamide
布林佐胺
更新于：2025-10-28
概要
基本信息
原研机构 |
非在研机构 |
权益机构- |
最高研发阶段批准上市 |
最高研发阶段(中国)批准上市 |
特殊审评- |
登录后查看时间轴
结构/序列
分子式C12H21N3O5S3 |
InChIKeyHCRKCZRJWPKOAR-JTQLQIEISA-N |
CAS号138890-62-7 |
关联
41
项与 布林佐胺 相关的临床试验CTRI/2024/07/071413
A Randomized, Double-masked, Active Controlled, Parallel Group, Two-arm, Multi Center,in-vivo Bioequivalence Study with Clinical Endpoint Comparing Brinzolamide OphthalmicSuspension, USP 1 Percent of Riconpharma LLC, USA to AZOPT® (Brinzolamide OphthalmicSuspension) 1 Percent of Novartis Pharmaceuticals Corporation, USA in subjects with Chronic OpenAngle Glaucoma or Ocular Hypertension in both eyes - Nil
CTRI/2023/06/054478
A multicenter, randomized, assessor-blinded, active controlled, parallel group, two arm, non-inferiority clinical trial for the comparison of efficacy and safety of a preservative-free Brinzolamide 10mg/ml + Brimonidine tartrate 2 mg/ml eye drops suspension (AZAD Pharma AG, Switzerland) and Simbrinza® (Brinzolamide 10 mg/ml + Brimonidine tartrate 2 mg/ml) eye drops suspension (Novartis Europharm Limited, Ireland ) in the treatment of elevated intraocular pressure in adult patients with open-angle glaucoma or ocular hypertension.
EUCTR2022-002524-12-BG
A prospective, phase III, multicenter, randomized, investigator-blinded, two-arm, parallel groups, non-inferiority clinical trial for the comparison of efficacy and safety of a preservative-free Brinzolamide 10mg/ml eye drops suspension (Brinzolamide 10mg/ml Eye Drops Suspension Preservative Free) as a test product versus AZOPT® 10 mg/ml eye drops suspension as reference product in the treatment of elevated intraocular pressure in adult patients with open-angle glaucoma or ocular hypertension
100 项与 布林佐胺 相关的临床结果
登录后查看更多信息
100 项与 布林佐胺 相关的转化医学
登录后查看更多信息
100 项与 布林佐胺 相关的专利（医药）
登录后查看更多信息
688
项与 布林佐胺 相关的文献（医药）2025-10-01Materials Today Bio
Brinzolamide encapsulated β-cyclodextrin-chondroitin sulfate nanocomplexes anchored chitosan/polycaprolactone nanofibers as an ocular insert for glaucoma treatment
Article
作者: Iqbal, Haroon ; Xiao, Run ; Lin, Fu ; Zhou, Dengming ; Liang, Yuanbo ; Razzaq, Anam ; Zhang, Haiyang
Glaucoma ranked second among the causes of blindness globally, necessitates the development of novel and effective therapeutic strategy. Anti-glaucoma eye drops as a topical dosage form are still considered as a method of choice for glaucoma treatment. However, a short ocular drug residence time of eye drops leads to poor bioavailability of drug which requires repeated dosing. Mucoadhesive nanofibers as a topical dosage form is promising for combating these challenges. In this study we introduce a novel hybrid nanodrug delivery system based on nanoparticles in nanofibers (NPs-in-NFs) for controlled release of brinzolamide (BRZ) in glaucoma treatment. The results showed that the assimilation of BRZ loaded NPs into electrospun NFs achieved various benefits such as sustained drug release with continuous rate, augmented ocular contact and residence time, precise dose delivery, prolonged therapeutic effect, reduced dose and its administration frequency, improved bioavailability, negligible incidence of systemic and visual side effects. Further, ex vivo studies revealed that the corneal permeation of NPs-in-NFs insert significantly increase compared to Azopt® eye drops with an average value of 62.34 ± 2.4 μg/cm2 and 39.06 ± 1.9 μg/cm2, respectively. NPs-in-NFs insert exhibited a prolonged terminal half-life (t 1/2) of about 6 h, compared to Azopt® eye drops (1h). Moreover, at 96h of dose administration, a significant decrease (14.48 ± 2.65 mm Hg) was observed in the IOP of NPs-in-NFs administered rabbits (21.06 ± 2.51 mm Hg) compared with Azopt® eye drops administered rabbits (35.54 ± 3.60 mm Hg). Thus, the combination of NPs and NFs into a single nanoplatform represents a promising strategy for advancing glaucoma treatment, prominence its potential in clinical application.
2025-07-01AMERICAN JOURNAL OF OPHTHALMOLOGY
Drugs Associated With Floppy Iris Syndrome: A Real-World Population-Based Study
Article
作者: Kwan, Angela T H ; Popovic, Marko M ; Mihalache, Andrew ; Lakhani, Moiz ; Hurley, Bernard ; Muni, Rajeev H
PURPOSE:
Intraoperative floppy iris syndrome (IFIS) is associated with an increased rate of severe intraoperative complications and greater visual morbidity during cataract surgery, particularly in females. To date, no postmarketing pharmacovigilance study has comprehensively examined all FDA-approved drugs for their association with IFIS development or explored potential sex differences. Understanding the risk factors for IFIS allows cataract surgeons to better stratify surgical risks and implement appropriate preoperative and intraoperative measures to ensure adequate management in high-risk patients.
DESIGN:
Retrospective pharmacovigilance clinical cohort study.
METHODS:
This population-based, observational study analyzed IFIS cases reported to the Food and Drug Administration Adverse Event Reporting System from October 2003 to March 2024 using OpenVigil 2.1. Disproportionality metrics, including reporting odds ratios (RORs), proportional reporting ratios (PRRs), and relative risk reductions, were used to assess signals for positive adverse reactions (n > 2, χ2 > 4, PRR > 2), compared to all other drugs. Subgroup analyses were also conducted by sex.
RESULTS:
Of 12,345,128 adverse event reports, 649 (0.0053%) involved IFIS. The majority of cases were reported by healthcare professionals (75.75%, n = 203), followed by consumers (12.69%, n = 34) and unknown sources (11.57%, n = 31). Drugs with the highest disproportionality for IFIS included imipramine (ROR = 251.66, 95% confidence interval [CI] = 157.53-402.02), tamsulosin (ROR = 171.44, 95% CI = 143.12-205.36), and chlorpromazine (ROR = 91.30, 95% CI = 49.91-167.03) (all P < .0001, IC025 > 0). Over-reported drug classes included α1-blockers, tricyclic antidepressants, atypical antipsychotics, carbonic anhydrase inhibitors, corticosteroids, 5α-reductase inhibitors, β-blockers, prostaglandin analogs, and β2-agonists. Among females, brinzolamide (ROR = 409.63, 95% CI = 196.78-852.73) and salbutamol (ROR = 67.12, 95% CI = 28.37-158.80) were disproportionately associated with IFIS (both P < .0001, IC025 > 0), whereas these associations were not observed in males.
CONCLUSIONS:
This analysis of over 20,000 drugs and 12 million reports highlights that, in addition to α1-blockers and atypical antipsychotics, tricyclic antidepressants are among the key agents most disproportionately associated with IFIS, with notable sex differences. These findings are crucial for informing perioperative counseling and surgical planning for cataract surgery.
2025-06-03CURRENT EYE RESEARCH
Comparison of the Effects of Timolol, Brinzolamide, Brimonidine and Netarsudil in a Rabbit Model of Water Loading-Induced Ocular Hypertension
Article
作者: Hino, Keisuke ; Sakurai, Kazushi ; Itoh, Shinsaku ; Kakumoto, Yusuke ; Yamashita, Daisuke ; Urashima, Hiroki ; Maruoka, Junya ; Takeji, Yasuhiro
PURPOSE:
This study aimed to compare the intraocular pressure (IOP)-lowering effects of timolol (a β-blocker), brinzolamide (a carbonic anhydrase inhibitor), brimonidine (an α2-agonist) and netarsudil (a rho kinase inhibitor) in rabbits.
METHODS:
The experiments were performed on 52 female New Zealand white rabbits. The IOP was measured in normotensive rabbits and in water loading-induced ocular hypertension model rabbits. Thirty microliters of timolol, brinzolamide, brimonidine, netarsudil or saline was administered topically to the randomly chosen eye. Ocular hypertension was induced by the oral administration of 60 mL/kg of tap water.
RESULTS:
In normotensive rabbits, the maximum IOP-lowering effects of timolol, brinzolamide, brimonidine, and netarsudil were 2.9 mmHg (2 h), 5.2 mmHg (1 h), 5.7 mmHg (2 h), and 3.3 mmHg (4 h), respectively. In water loading-induced ocular hypertension model rabbits, the maximum IOP-lowering effects of timolol, brinzolamide, brimonidine, and netarsudil were 3.6, 5.0, 12.2, and 5.0 mmHg, respectively. The IOP-lowering effects of brimonidine and netarsudil were sustained until 90 min after water loading.
CONCLUSION:
This study showed that timolol, brinzolamide, brimonidine and netarsudil have IOP-lowering effects in normotensive rabbits and in water loading-induced ocular hypertension model rabbits. In an ocular hypertension rabbit model, brimonidine and netarsudil, which promote aqueous humor outflow, exhibited stronger IOP-lowering effects than timolol and brinzolamide, which suppress aqueous humor production. These results could provide data for characterizing each medication. These data may aid in the development of new glaucoma medications through the combination of existing medications.
100 项与 布林佐胺 相关的药物交易
登录后查看更多信息
研发状态
批准上市
10 条最早获批的记录, 后查看更多信息
登录
| 适应症 | 国家/地区 | 公司 | 日期 |
|---|---|---|---|
| 青光眼 | 日本 | 2002-12-10 | |
| 开角型青光眼 | 美国 | 1998-04-01 | |
| 高眼压症 | 美国 | 1998-04-01 |
未上市
10 条进展最快的记录, 后查看更多信息
登录
| 适应症 | 最高研发状态 | 国家/地区 | 公司 | 日期 |
|---|---|---|---|---|
| 虹膜色素剥脱综合征 | 临床阶段不明 | 美国 | 2003-09-01 |
登录后查看更多信息
临床结果
临床结果
适应症
分期
评价
查看全部结果
临床3期 | 599 | (BRIN-20-01) | 醖鬱製鏇積網簾範蓋鹽(艱積選積構遞觸憲選齋) = 顧鏇壓鏇願醖構遞獵夢 蓋襯鹽膚餘觸憲壓艱膚 (廠願廠齋繭選構製齋築, 2.290) 更多 | - | 2024-01-18 | ||
(Azopt®) | 醖鬱製鏇積網簾範蓋鹽(艱積選積構遞觸憲選齋) = 襯壓窪願廠壓憲廠糧窪 蓋襯鹽膚餘觸憲壓艱膚 (廠願廠齋繭選構製齋築, 2.363) 更多 | ||||||
临床3期 | 495 | (Perrigo Active) | 餘窪鑰壓膚鏇願鬱繭網(糧鹹繭鑰艱範繭鑰簾製) = 範淵鹹簾衊觸繭築襯獵 積夢醖範襯製衊鏇製醖 (遞壓繭積願鏇齋膚窪糧, 2.713) 更多 | - | 2023-03-06 | ||
(Reference Active) | 餘窪鑰壓膚鏇願鬱繭網(糧鹹繭鑰艱範繭鑰簾製) = 遞衊齋鹽網鑰襯鑰夢顧 積夢醖範襯製衊鏇製醖 (遞壓繭積願鏇齋膚窪糧, 2.719) 更多 | ||||||
临床1/2期 | 637 | (Brinzolamide 1% Ophthalmic Suspension) | 壓淵餘遞夢鏇窪構蓋顧(襯獵遞願獵憲廠襯製淵) = 鹽醖襯襯遞艱願襯構獵 壓製蓋選顧鬱繭衊淵繭 (蓋鏇淵築鹹壓簾衊範鏇, 3.269) 更多 | - | 2021-06-09 | ||
(Azopt 1% Ophthalmic Suspension) | 壓淵餘遞夢鏇窪構蓋顧(襯獵遞願獵憲廠襯製淵) = 窪積壓範顧淵鑰網襯鹹 壓製蓋選顧鬱繭衊淵繭 (蓋鏇淵築鹹壓簾衊範鏇, 3.183) 更多 | ||||||
临床3期 | 258 | (Brinzolamide 1% Ophthalmic Suspension) | 鬱遞構衊鑰齋夢範繭簾(範憲鑰窪襯夢鹹顧襯願) = 遞簾築衊構艱網遞膚窪 積構窪廠鹽衊蓋艱齋醖 (糧艱壓鬱鑰衊餘繭衊繭, 3.21) 更多 | - | 2021-06-09 | ||
(Azopt 1% Ophthalmic Suspension) | 鬱遞構衊鑰齋夢範繭簾(範憲鑰窪襯夢鹹顧襯願) = 遞鹹淵範窪鹽齋齋獵廠 積構窪廠鹽衊蓋艱齋醖 (糧艱壓鬱鑰衊餘繭衊繭, 3.37) 更多 | ||||||
临床3期 | - | 鹽願範淵壓艱膚製齋廠(夢獵齋築鹽壓鹽製齋構) = 餘遞網鑰製夢遞繭壓願 醖範夢憲繭觸築餘築膚 (鏇繭糧獵襯廠構遞簾淵, 0.16) | 积极 | 2014-12-01 | |||
鹽願範淵壓艱膚製齋廠(夢獵齋築鹽壓鹽製齋構) = 選獵衊夢艱壓齋鑰選餘 醖範夢憲繭觸築餘築膚 (鏇繭糧獵襯廠構遞簾淵, 0.16) | |||||||
临床3期 | 660 | 餘淵鑰網廠願顧簾膚蓋(範夢壓製鏇膚範鏇鬱艱) = 觸鬱築選簾選艱選糧觸 餘鬱繭構遞壓襯顧淵繭 (構積簾糧壓獵製鏇襯醖, 2.97) | 积极 | 2014-04-01 | |||
餘淵鑰網廠願顧簾膚蓋(範夢壓製鏇膚範鏇鬱艱) = 夢膚餘襯網觸獵製糧遞 餘鬱繭構遞壓襯顧淵繭 (構積簾糧壓獵製鏇襯醖, 3.64) | |||||||
临床3期 | - | 690 | 積積鹽鏇築範餘積膚簾(繭齋艱鬱構醖製齋鏇遞) = At 6 months, the most common treatment-related AEs for BBFC were eye irritation (6.3%), eye allergy (6.3%), and conjunctivitis (5.0%), for brinzolamide they were dysgeusia (10.3%) and blurred vision (6.8%), and for brimonidine they were conjunctivitis (6.0%) and conjunctivitis allergic (4.3%) 觸築鏇願夢選觸鏇夢壓 (衊網齋窪膚窪窪廠遞範 ) | 积极 | 2013-06-01 | ||
临床3期 | 660 | Fixed-combination brinzolamide, 1%, and brimonidine, 0.2% | 繭鏇選膚積願齋鑰鬱淵(顧顧鑰鹽顧遞築襯夢鑰) = One of 10 serious adverse events (chest pain, brinzolamide group) was judged as treatment related 窪醖構膚遞蓋願選窪糧 (膚膚積繭憲餘衊淵顧衊 ) 更多 | - | 2013-06-01 | ||
临床4期 | 86 | (Xalatan + Azopt) | 選餘壓夢蓋鹹壓醖糧膚(淵膚構艱觸襯齋觸艱襯) = 製艱糧鹹顧夢襯製蓋蓋 憲餘願構鑰壓範衊夢窪 (鬱築願襯願夢遞衊構鏇, 3.03) 更多 | - | 2012-08-16 | ||
Placebo eye drops+Latanoprost (Xalatan + Placebo) | 選餘壓夢蓋鹹壓醖糧膚(淵膚構艱觸襯齋觸艱襯) = 餘積夢積醖餘觸餘鹹鬱 憲餘願構鑰壓範衊夢窪 (鬱築願襯願夢遞衊構鏇, 2.63) 更多 | ||||||
临床4期 | - | Placebo | 鑰醖簾鏇糧鏇選積醖鹽(壓繭遞糧網醖糧夢衊製) = 觸鹹餘顧糧鹹鏇簾蓋觸 積範淵網鬱廠築艱夢積 (膚衊獵鏇醖築鬱淵遞簾 ) | - | 2012-01-01 | ||
鑰醖簾鏇糧鏇選積醖鹽(壓繭遞糧網醖糧夢衊製) = 夢餘製網夢願鹹觸積糧 積範淵網鬱廠築艱夢積 (膚衊獵鏇醖築鬱淵遞簾 ) |
登录后查看更多信息
转化医学
使用我们的转化医学数据加速您的研究。
登录
或
药物交易
使用我们的药物交易数据加速您的研究。
登录
或
核心专利
使用我们的核心专利数据促进您的研究。
登录
或
临床分析
紧跟全球注册中心的最新临床试验。
登录
或
批准
利用最新的监管批准信息加速您的研究。
登录
或
特殊审评
只需点击几下即可了解关键药物信息。
登录
或
生物医药百科问答
全新生物医药AI Agent 覆盖科研全链路，让突破性发现快人一步
立即开始免费试用!
智慧芽新药情报库是智慧芽专为生命科学人士构建的基于AI的创新药情报平台，助您全方位提升您的研发与决策效率。
立即开始数据试用!
智慧芽新药库数据也通过智慧芽数据服务平台，以API或者数据包形式对外开放，助您更加充分利用智慧芽新药情报信息。
生物序列数据库
生物药研发创新
免费使用
化学结构数据库
小分子化药研发创新
免费使用